Hepion Pharmaceuticals, Inc. (HEPA)

US — Healthcare Sector
Peers: TECX  OCEA  ENVB  ELEV  HOTH  PSTV  PHIO  BXRXQ  SONN 

Automate Your Wheel Strategy on HEPA

With Tiblio's Option Bot, you can configure your own wheel strategy including HEPA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol HEPA
  • Rev/Share 0.0
  • Book/Share 1.3734
  • PB 0.0524
  • Debt/Equity 0.1351
  • CurrentRatio 6.7511
  • ROIC -2.6139

 

  • MktCap 790294.0
  • FreeCF/Share -5.5407
  • PFCF -0.0503
  • PE -0.0124
  • Debt/Assets 0.0833
  • DivYield 0
  • ROE -12.6792

 

  • Rating B
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 5
  • P/B Score 5
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC
HEPA
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral

MORRISTOWN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that it has entered into a binding letter of intent (“LOI”) with New Day Diagnostics LLC to in-license diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma (HCC). The celiac, respiratory multiplex and H. pylori tests have CE marks and are eligible to be sold in Europe at the present time.

Read More
image for news Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC

About Hepion Pharmaceuticals, Inc. (HEPA)

  • IPO Date 2014-02-10
  • Website https://www.hepionpharma.com
  • Industry Biotechnology
  • CEO John Patrick Brancaccio CPA
  • Employees 22
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.